An observational study in Narcolepsy, sponsored by Avadel. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Avadel (part of Alkermes, Inc.) · Observational
This is an observational study of LUMRYZ prescribed in clinical practice. Patients are asked if they would be willing to complete questionnaires over a 4-month period after starting LUMRYZ. The questionnaires ask about narcolepsy symptoms, experience with LUMRYZ, and quality of life.
157 studies on the registry are indexed under Narcolepsy; 37 are open to participants now.
This study's enrollment of 71 is below the median of 135 across 38 observational studies indexed under Narcolepsy.
Browse Narcolepsy studies →Avadel is the lead sponsor of 4 studies on the registry; none are open to participants now.
First submitted before Avadel became part of Alkermes, Inc..
Counted across the registry records on this site, refreshed daily.
Adults (18 years and older) with a diagnosis of Type 1 or Type 2 narcolepsy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The cohort is comprised of patients prescribed LUMRYZ in clinical practice. All dosing decisions are made by the clinician.
Drug: LUMRYZ
Prescribed for narcolepsy in accordance with product label.
Epworth Sleepiness Scale
Change from the first visit (baseline), prior to start of LUMRYZ, to Month 4; measure of sleepiness with total possible score of 0-24 (higher score equivalent to higher sleepiness)
Time frame: Baseline to Month 4
Narcolepsy Severity Scale
Change from the first visit (baseline), prior to start of LUMRYZ, to Month 4; measure of narcolepsy symptom frequency and impact on daily life with total possible score from 0-57 (higher score indicates more frequent and severe symptoms)
Time frame: Baseline to Month 4
Sheehan Disability Scale
Change from the first visit (baseline), prior to start of LUMRYZ, to Month 4; measure of disruption to normal activities using a 0-10 scale, along with the number of days missed and/or underproductive at work/school
Time frame: Baseline to Month 4
Patient Global Impression of Change
Measure of improvement at Month 4 using a scale of 1 (very much improved) to 7 (very much worse); scored by patient
Time frame: Month 4
Clinical Global Impression of Change
Measure of improvement at Month 4 using a scale of 1 (very much improved) to 7 (very much worse); scored by clinician
Time frame: Month 4
Adverse Reactions
Clinician-directed interview for common adverse reactions
Time frame: Month 1, Month 2, Month 3, Month 4
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.